-
- 中川 秀己
- 東京慈恵会医科大学皮膚科学
-
- 相場 節也
- 東北大学大学院医学系研究科内科病態学(皮膚科学)
-
- 朝比奈 昭彦
- 東京大学大学院医学系研究科感覚・運動機能医学(皮膚科学)
-
- 飯塚 一
- 旭川医科大学皮膚科学
-
- 五十嵐 敦之
- NTT東日本関東病院皮膚科
-
- 梅澤 慶紀
- 東海大学医学部専門診療学系皮膚科学領域
-
- 江藤 隆史
- 東京逓信病院皮膚科
-
- 大槻 マミ太郎
- 自治医科大学皮膚科学
-
- 小澤 明
- 東海大学医学部専門診療学系皮膚科学領域
-
- 瀧川 雅浩
- 浜松医科大学皮膚科学
-
- 中山 樹一郎
- 福岡大学医学部皮膚科学
-
- 水谷 仁
- 三重大学医学部皮膚科学
-
- 根本 治
- 札幌皮膚科クリニック
-
- 古江 増隆
- 九州大学大学院医学研究院皮膚科学
-
- 古川 福実
- 和歌山県立医科大学医学部皮膚科学
-
- 森田 明理
- 名古屋市立大学大学院医学研究科加齢・環境皮膚科学
-
- 矢口 均
- 自衛隊中央病院皮膚科
-
- 両角 國男
- 名古屋第二赤十字病院腎臓内科
書誌事項
- タイトル別名
-
- A Consensus Conference Report on Psoriasis Therapy with Cyclosporine MEPC
- 生涯教育講座 シクロスポリンMEPCによる乾癬治療のガイドライン 2004年度版コンセンサス会議報告
- ショウガイ キョウイク コウザ シクロスポリン MEPC ニ ヨル カンセンチリョウ ノ ガイドライン 2004ネンドバン コンセンサス カイギ ホウコク
この論文をさがす
抄録
The efficacy of cyclosporine microemulsion preconcentrate (cyclosporine MEPC) in the treatment of severe psoriasis is well-established, as demonstrated by numerous clinical trials. However, many dermatologists still continue to have some concerns regarding its use. These are mainly related to preconceptions about its side effects which include renal impairment and hypertension, and to the lack of guideline for the appropriate and effective use of cyclosporine MEPC in the treatment of severe psoriasis. A Japanese consensus conference was convened following an international conference held in Paris in order to amend The Japanese Guideline for Psoriasis Therapy with Cyclosporine MEPC. Expert reviewers presented and deliberated Japanese as well as international evidence on cyclosporine MEPC related to clinical efficacy, patient selection, and profiles of adverse drug reactions. They reached a consensus as to the proposed recommendations of the use of cyclosporine MEPC. The definition of difficult-to-treat in the context of patient selection for cyclosporine MEPC was changed from a PASI score ≧ 18 to 12, and “patients unsatisfied with the effects of their current therapy” was newly added concerning the impact of psoriasis on patients’ QOL in QOL assessments by patients. Because a dose of 2.5mg/kg/day has been reported to show adequate efficacy, a suggested range of 2.5 to 5.0mg/kg/day was set. Because, at the dose of 2.5 mg/kg/day, 70% improvement of PASI scores was achieved at 12-weeks, it was recommended that the course of subsequent therapy should be re-examined based on the efficacy checked after three months following the start of therapy. Patients’ QOL and patient assessment of efficacy were also added as efficacy outcome measures in addition to PASI score, affected body surface area, and degrees of pustules and pruritus. Serum creatinine level (S-Cr) was recommended as a measure for assessing renal impairment, and it was stated that a detailed kidney test should be performed by a renal specialist if S-Cr levels do not show any improvement about one month after withdrawal of treatment. The Guidelines will be revised in 2004 based on the consensus reached.
収録刊行物
-
- 日本皮膚科学会雑誌
-
日本皮膚科学会雑誌 114 (6), 1093-1105, 2004
公益社団法人 日本皮膚科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205739476608
-
- NII論文ID
- 130004708332
- 10013672062
-
- NII書誌ID
- AN00196602
-
- ISSN
- 13468146
- 0021499X
-
- NDL書誌ID
- 025120841
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可